CVE-2008-2452
Cross-site scripting (XSS) vulnerability in the Questionaire (aka pbsurvey) extension 1.2.0 and...
Cross-site scripting (XSS) vulnerability in the Questionaire (aka pbsurvey) extension 1.2.0 and earlier for TYPO3 allows remote attackers to inject arbitrary web script or HTML via unspecified vectors.
Exploit likelihood
What each source reports
NVD Score used
Cross-site scripting (XSS) vulnerability in the Questionaire (aka pbsurvey) extension 1.2.0 and earlier for TYPO3 allows remote attackers to inject arbitrary web script or HTML via unspecified vectors.
- Record
CVE-2008-2452- CVSS 2.0
- 4.3 Medium
AV:N/AC:M/Au:N/C:N/I:P/A:N - Weakness
- CWE-79
- Updated
- 2026-11-02
CVE List No score
Cross-site scripting (XSS) vulnerability in the Questionaire (aka pbsurvey) extension 1.2.0 and earlier for TYPO3 allows remote attackers to inject arbitrary web script or HTML via unspecified vectors.
- Record
CVE-2008-2452- Updated
- 2026-11-02
EUVDEUVD-2008-2447 No score
Cross-site scripting (XSS) vulnerability in the Questionaire (aka pbsurvey) extension 1.2.0 and earlier for TYPO3 allows remote attackers to inject arbitrary web script or HTML via unspecified vectors.
- Record
EUVD-2008-2447- Updated
- 2026-11-03
GitHub AdvisoriesGHSA-vc7h-fm6p-6vrv No score
Cross-site scripting (XSS) vulnerability in the Questionaire (aka pbsurvey) extension 1.2.0 and...
Cross-site scripting (XSS) vulnerability in the Questionaire (aka pbsurvey) extension 1.2.0 and earlier for TYPO3 allows remote attackers to inject arbitrary web script or HTML via unspecified vectors.
- Record
GHSA-vc7h-fm6p-6vrv- Weakness
- CWE-79
- Updated
- 2026-11-02
Affected products
History
| Recorded | Changed | Sources |
|---|---|---|
| aliases | EUVD | |
| first indexed | CVE List, GitHub Advisories, NVD |
Dates are when Every CVE recorded each change. Upstream dates may differ.
In short
CVE-2008-2452 is a medium vulnerability (CVSS 4.3) in Inmedias Questionaire, published May 27, 2008. No source lists public exploit code. EPSS puts the chance of exploitation in the next 30 days at 0.99%, the 62nd percentile. No source names a fixed version.